Wuhan Thalys Med Tech Co Ltd (603716) — Capital Reinvestment Ratio
Wuhan Thalys Med Tech Co Ltd (603716) has a Capital Reinvestment Ratio of 0.03x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥54.57 Million) in capital expenditures (CN¥1.57 Million). See 603716 net asset quality score to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Wuhan Thalys Med Tech Co Ltd Capital Reinvestment Ratio (2012–2024)
This chart tracks Wuhan Thalys Med Tech Co Ltd's Capital Reinvestment Ratio across 9 annual periods. Check Wuhan Thalys Med Tech Co Ltd (603716) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Wuhan Thalys Med Tech Co Ltd (2012–2024)
Year-by-year Capital Reinvestment Ratio for Wuhan Thalys Med Tech Co Ltd from 2012 to 2024. For live market cap and broader valuation context, see 603716 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.23x | CN¥99.60 Million | CN¥23.21 Million | ▼ -28.1% |
| 2023 | 0.32x | CN¥125.89 Million | CN¥40.83 Million | ▼ -83.3% |
| 2022 | 1.94x | CN¥28.12 Million | CN¥54.64 Million | ▼ -84.9% |
| 2020 | 12.84x | CN¥9.94 Million | CN¥127.70 Million | ▲ +1150.0% |
| 2019 | 1.03x | CN¥93.92 Million | CN¥96.49 Million | ▲ +17.0% |
| 2015 | 0.88x | CN¥46.11 Million | CN¥40.47 Million | ▼ -16.8% |
| 2014 | 1.06x | CN¥30.07 Million | CN¥31.73 Million | ▼ 0.0% |
| 2013 | 1.06x | CN¥32.54 Million | CN¥34.35 Million | ▼ -93.1% |
| 2012 | 15.20x | CN¥2.70 Million | CN¥41.04 Million | — |